0001193125-21-233293.txt : 20210802 0001193125-21-233293.hdr.sgml : 20210802 20210802162156 ACCESSION NUMBER: 0001193125-21-233293 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210731 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210802 DATE AS OF CHANGE: 20210802 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDICINOVA INC CENTRAL INDEX KEY: 0001226616 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330927979 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33185 FILM NUMBER: 211136310 BUSINESS ADDRESS: STREET 1: 4275 EXECUTIVE SQUARE STREET 2: SUITE 300 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 858-373-1500 MAIL ADDRESS: STREET 1: 4275 EXECUTIVE SQUARE STREET 2: SUITE 300 CITY: LA JOLLA STATE: CA ZIP: 92037 8-K 1 d211886d8k.htm 8-K 8-K
MEDICINOVA INC false 0001226616 0001226616 2021-07-31 2021-07-31

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 31, 2021

 

 

MEDICINOVA, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-33185   33-0927979

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

4275 Executive Square, Suite 300

La Jolla, CA 92037

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (858) 373-1500

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Common Stock, $0.001 par value

 

MNOV

 

The Nasdaq Stock Market LLC

(Title of each class)   (Trading symbol(s))  

(Name of each exchange

on which registered)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 5.02

Departure of Directors or Certain Officers; Election; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective July 31, 2021, Edward Stepanow resigned as Chief Financial Officer of MediciNova, Inc. (the “Company”).

In addition, effective August 1, 2021, the Board appointed Douglas Paulin, CPA, of the accounting services firm Signature Analytics San Diego LLC (“Signature Analytics”) to serve as Chief Financial Officer and Principal Financial Officer of the Company. Mr. Paulin replaces Mr. Stepanow. Mr. Stepanow had also served as the Company’s Chief Financial Officer through a services agreement (the “Services Agreement”) between the Company and Signature Analytics. In connection with Mr. Paulin’s appointment as Chief Financial Officer, the Company entered into an amendment to the Services Agreement with Signature Analytics for the provision of Mr. Paulin’s services, which is also effective as of August 1, 2021. Under the Services Agreement, as amended, the Company will continue to pay pre-approved hourly rates for the services provided under the Services Agreement. The current term of the Services Agreement, as amended, will expire on August 1, 2022 with automatic annual renewals, subject to earlier termination according to its terms.

Mr. Paulin, age 46, joined Signature Analytics in July 2020. From June 2019 until March 2020, Mr. Paulin served as Head of Finance and Accounting at AerNos, Inc., a consumer and commercial nanotechnology company. From March 2016 until December 2018, Mr. Paulin served as Director of EMEA Finance at Sonos, Inc. (Nasdaq:SONO), a smart speaker company. From 2013 to 2016, Mr. Paulin served as Chief Financial Officer at Autonet Mobile, a company that provides in-vehicle telematics and marketing software for automotive dealerships and aftermarket service providers. Prior to this, Mr. Paulin served as Director of Finance at Zego, formerly PayLease. Mr. Paulin received a Bachelor of Science in Finance and a minor in Management Information Systems from Babson College. Mr. Paulin holds an active license in the state of California.

There are no family relationships between Mr. Paulin and any of the Company’s other directors or executive officers, and Mr. Paulin does not have any direct or indirect material interests in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No.   

Description

99.1    Services Agreement, dated August 1, 2021, by and between the Company and Signature Analytics LLC.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    MEDICINOVA, INC.
Dated: August 2, 2021     By:  

/s/ Yuichi Iwaki

      Yuichi Iwaki, M.D., Ph.D.
      President and Chief Executive Officer

 

3

EX-99.1 2 d211886dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

SERVICES AGREEMENT

This Agreement is entered into August 1, 2021 between Signature Analytics LLC (“SA”) and MediciNova, Inc. (“Client”) located at 4275 Executive Square, Suite 300, La Jolla, CA 92037.

1. Services. During the term of this Agreement, SA will provide financial and accounting services (“Services”) as agreed from time to time by Client and SA. All such Services shall be performed by SA and its agents in conformity with the highest professional and ethical standards generally accepted as applicable to such Services. The term of this Agreement will be one year with automatic annual renewals. However, Client or SA may terminate this Agreement at any time by giving at least thirty (30) days’ prior written notice. Any notices under this Agreement may be delivered by hand, email, U.S. mail or courier. SA has the sole discretion to place and remove the Service Providers (as defined in Appendix A) working with Client. SA will report and pay any income tax withholdings, disability, unemployment, workers’ compensation, employee benefits, and similar items for its employees. Fees and Hourly Rates of the Service Providers are stated in the attached Appendix A, which is included as part of this Agreement.

2. Nondisclosure. SA shall only use and/or disclose Client’s financial data and records (“Confidential Information”) as reasonably necessary for the purposes of this Agreement. This restriction will not apply to information that (a) is already known by SA at the time of receipt; (b) becomes publicly known through no wrongful act of SA; (c) is rightfully received from a third party without obligation of confidentiality; or (d) is required to be disclosed by applicable law.

3. On-Site Representatives. If any Service Provider of SA is required to go on-site to the offices of Client, Client agrees to follow all government guidelines pertaining to COVID-19 safety. If the Service Provider does not feel safe from COVID-19 on-site, or at the instruction of SA, that person may immediately leave, which shall not constitute a breach of this Agreement. The parties shall then work promptly and in good faith to determine a reasonable solution.

4. Placement. During the term of this Agreement and for 6 months thereafter, if Client directly or indirectly hires any Service Provider assigned to Client, either as a full-time or part-time employee or independent contractor, it is agreed Client will pay SA the following placement fee(s): CFO, VP of Accounting and Process, and Chief Accounting Officer $85,000; Controller and Director of Process Implementation $60,000; Accounting Manager $40,000; Senior Accountant $25,000; and Staff Accountant and Bookkeeper $20,000. Client acknowledges that if Client hires any of the Service Providers: (a) SA invested substantial time and money to locate, hire and train its Service Providers, and SA will be required to do so again, (b) each of SA’s Service Providers perform similar, concurrent services for multiple SA clients, so SA will be required to cover its other clients, and (c) the unique nature of SA’s business model creates additional risks and costs. Therefore, Client and SA agree these fees accurately reflect the reasonable value of SA’s time, costs and other financial considerations.

5. Limiting Conditions. All Services will be subject to the following conditions: (a) all statements, communications, results, reviews, reports and other deliverables provided by SA as part of the Services (collectively, “SA Reports”) will be solely for the use of Client, including for purposes of Client’s disclosure and reporting obligations under the Securities Act of 1933 and the Securities Exchange Act of 1934, in each case as amended (the “Acts”), the rules and regulations under the Acts and Client’s obligations as the issuer of securities on one or more stock exchanges; (b) information in the SA Reports may not be modified in any way except by SA; (c) SA will not express an opinion or any other form of assurance regarding the Client’s financial statements or otherwise, and no SA Reports should be interpreted as such; (d) the Services will not be provided as Certified Public Accountant services; (e) the Services will not include any financial audit or audit of financial statements, nor may SA’s name be used in association with any audit; (f) the SA Reports may not be relied upon to discover errors, fraud or illegal acts, but if SA discovers any such matters, SA will use reasonable efforts to bring them to Client’s attention; and (g) Client’s management shall be solely responsible for internal controls, legal compliance, accuracy of financial statements, information and data, conformity with GAAP, and the review of all SA Reports before they are used or relied upon. For clarity, SA does not validate or confirm the accuracy of the data or information given to SA by Client.

6. Limits on Liability. Indemnification. (a) SA WILL NOT BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL, OR CONSEQUENTIAL DAMAGES, OR FOR ANY LOSS OF PROFITS, DATA, REVENUE, GOODWILL OR ANTICIPATED SAVINGS RESULTING FROM OR IN ANY WAY RELATED TO THE SERVICES, THIS AGREEMENT, OR ANY OTHER DISPUTE BETWEEN THE PARTIES, EVEN IF SA HAS BEEN INFORMED OF THE POSSIBILITY THEREOF, AND DESPITE ANY FAILURE OF THE ESSENTIAL PURPOSE OF THIS AGREEMENT OR ANY LIMITED REMEDY UNDER THIS AGREEMENT. ADDITIONALLY, THE TOTAL AGGREGATE LIABILITY OF SA FOR ANY AND ALL CLAIMS, LOSSES, EXPENSES AND DAMAGES OF ANY NATURE (INCLUDING ATTORNEYS’ FEES AND COSTS) RESULTING FROM, OR IN ANY WAY RELATED TO, THE SERVICES, THIS AGREEMENT, OR ANY OTHER DISPUTE BETWEEN THE PARTIES, SHALL BE LIMITED TO THE GREATER OF $25,000 OR THE FEES ACTUALLY PAID TO SA IN THE PRIOR 6 MONTHS FOR THE SERVICES THAT ARE THE SUBJECT OF THE CLAIM. OTHER THAN LIABILITY FOR FRAUD, WILLFUL INJURY TO PERSONS OR PROPERTY, OR VIOLATION OF LAW, THE AGGREGATE LIMITATIONS OF LIABILITY IN THE FOREGOING SENTENCE APPLY TO ANY AND ALL LIABILITY AND CAUSES OF ACTION (INCLUDING NEGLIGENCE), HOWEVER ALLEGED OR ARISING. SOME STATES OR OTHER JURISDICTIONS DO NOT PERMIT CERTAIN LIMITATIONS ON LIABILITY SO THESE LIMITATIONS WILL APPLY TO THE MAXIMUM EXTENT PERMITTED UNDER APPLICABLE LAW. (b) Client is concurrently herewith entering into an Indemnity Agreement (the “Indemnity Agreement”) with SA’s employee, Douglas Paulin, who will serve as Client’s Chief Financial Officer in connection with the services to be provided by SA hereunder. Client shall indemnify and otherwise provide benefits to SA and each of its officers, directors, managers, members, employees, agents, affiliates, successors and assigns (collectively, the “SA Indemnitees”) to the same extent as if each such SA Indemnitee was the “Indemnitee” under the Indemnity Agreement and such SA Indemnitee qualified as an “agent” of Client under the Indemnity Agreement.

7. Other Provisions. This Agreement (a) does not create any agency, partnership, joint venture or fiduciary relationship; (b) ,including Appendix A and the Credit Card / ACH Transfer Authorization, embodies the entire contract between the parties pertaining to its subject matter and supersedes any and all prior or contemporaneous written or oral promises, agreements or representations, and any modifications must be in writing with signatures of both parties; (c) cannot be waived by failure to enforce any provision except in writing; (d) may be signed in counterparts and electronic and other facsimile signed copies will be binding together as the original; (e) will be construed as severable, so the invalidity or unenforceability of any provision will not affect any other provisions of this Agreement; (f) is governed by California law, without reference to its conflict or choice of laws principles, and any legal preceding arising out of or in any way related to this Agreement shall be brought exclusively in the state or federal court in San Diego County, California and Client expressly consents to

 

OFFICE LOCATIONS: SAN DIEGO, ORANGE COUNTY, LOS ANGELES    Page 1 of 3
website: signatureanalytics.com   


LOGO

 

the personal jurisdiction of such courts; (g) cannot be assigned without the written consent of the other party, except an assignment by merger, consolidation or sale of all or substantially all of the transferring party’s equity or assets; and (h) is signed by the persons below with the full power and authority of the respective parties. The obligation to pay fees and late fees, and Sections 4, 5, 6, and 7 will survive any termination of this Agreement. Additionally, Section 2 shall survive for a period of 2 years after termination of this Agreement.

 

Signature Analytics LLC     MediciNova, Inc.
By:  

/s/ Jason Kruger

    By:  

/s/ Yuichi Iwaki

Jason Kruger     Yuichi Iwaki, M.D., Ph.D.
President     President and Chief Executive Officer

 

OFFICE LOCATIONS: SAN DIEGO, ORANGE COUNTY, LOS ANGELES    Page 2 of 3
website: signatureanalytics.com   


LOGO

 

Appendix A to Services Agreement

Fees and Hourly Rates

Fees. Client will pay a deposit at signing, to be applied against any late or final invoices. The initial Estimated Monthly Fee Range for Services is based on the Hourly Rates below.

 

Estimated Monthly Recurring Fee

   $ 5,000         $ 25,000  

Estimated Project Fees

   $ N/A        to      $ N/A  

Monthly Technology Platform Cost

     N/A        

Minimum Monthly Fee

     N/A        

Deposit (equal to low end of the fee range)

   $ 0        

Hourly Rates.

 

“Service Provider”

   Current Rate  

Market Leader / CFO

   $ 300 - $400/hr  

CFO

   $ 270 - $350/hr  

VP Finance / Sr. Controller

   $ 235 - $265/hr  

Director

   $ 200 - $235/hr  

Controller

   $ 195 - $225/hr  

Accounting Manager

   $ 150 - $185/hr  

Senior Accountant

   $ 120 - $145/hr  

Staff Accountant

   $ 95 - $110/hr  

Junior Staff Accountant

   $ 65 - $85/hr  

FIT Manager

   $ 210 - $275/hr  

FIT Analyst

   $ 110 - $165/hr  

Payments and Late Payments. Invoices will be delivered 1 time per month, on approximately the 1st of each month. Client will pay by check within the terms as stated on the invoice.

SA may change pricing or payment terms upon delivery of notice to Client. Regardless of when this Agreement is signed, on January 1 each year, the Deposit, Fee Ranges, Minimum Monthly Fee, and Service Provider rates will all increase by 5%.

Payments that are not received within 30 days after the date of the invoice will be considered delinquent and will be subject to a 10% per annum late fee. SA will be entitled to recover, and Client will be responsible for paying to SA, all collection expenses incurred by SA, including, without limitation, attorney fees and costs.

 

OFFICE LOCATIONS: SAN DIEGO, ORANGE COUNTY, LOS ANGELES    Page 3 of 3
website: signatureanalytics.com   
EX-101.SCH 3 mnov-20210731.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 mnov-20210731_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 mnov-20210731_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g211886dsp.jpg GRAPHIC begin 644 g211886dsp.jpg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d211886d8k_htm.xml IDEA: XBRL DOCUMENT 0001226616 2021-07-31 2021-07-31 MEDICINOVA INC false 0001226616 8-K 2021-07-31 DE 001-33185 33-0927979 4275 Executive Square Suite 300 La Jolla CA 92037 (858) 373-1500 false false false false Common Stock, $0.001 par value MNOV NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Jul. 31, 2021
Cover [Abstract]  
Entity Registrant Name MEDICINOVA INC
Amendment Flag false
Entity Central Index Key 0001226616
Document Type 8-K
Document Period End Date Jul. 31, 2021
Entity Incorporation State Country Code DE
Entity File Number 001-33185
Entity Tax Identification Number 33-0927979
Entity Address, Address Line One 4275 Executive Square
Entity Address, Address Line Two Suite 300
Entity Address, City or Town La Jolla
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92037
City Area Code (858)
Local Phone Number 373-1500
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value
Trading Symbol MNOV
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( +J" E,'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "Z@@)37B^: ^X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2@,Q$(9?17+?G6R*(F&;B^*I!<&"XBTDTS:XR89D9+=O[VYLMX@^@,?,_/GF M&YC61&GZA,^ICYC(8;X9?1>R-''-CD11 F1S1*]S/27"U-SWR6N:GND 49L/ M?4 0G-^!1])6DX896,6%R%1KC30)-?7IC+=FP@R4H:D;8&J> M&$]CU\(5,,,(D\_?!;0+L53_Q)8.L'-RS&Y)#<-0#ZN2FW9HX&V[>2GK5BYD MTL'@]"L[2:>(:W:9_+IZ>-P],26X:"I^7W&Q$UR*1MZ*]]GUA]]5V/?6[=T_ M-KX(JA9^W87Z E!+ P04 " "Z@@)3F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M +J" E/^1E5A1P0 -80 8 >&PO=V]R:W-H965T&UL MG9A=<^(V%(:OM[]"P_2BG4EB2PY?.X090MB6W7S00'=GVNF%L 5H(EM>60[D MW_?($)NVYICI3;!LG]>/=*3W2!ELM7G)-D)8LHM5DMVT-M:F'STO"SM$?UX MR]HNH'CCJQ3;[.B:N*XLM7YQC6ETT_(=D5 BM$Z"P\^K& NEG!)P?#^(MLIO MNL#CZW?U3T7GH3-+GHFQ5M]D9#A0 1AJE15_R7;_ M[K7?(F&>61T?@H$@ELG^E^\. W$4$- 3 >P0P KN_8<*RCMN^7!@])88]S:H MN8NBJT4TP,G$965N#3R5$&>'=SK,89 MX4E$)HF5]HU,DWVV8=0&GH6/N%>] M\"!XNQ=D)P0_Y^J*!/2",)_1?X9[P%8"LA*0%7K!";VQ?A6&_#E:9M9 "O]" M)(-2,B@DKT]('KKY+-;2B4+G'WDLZKJ*ZSQ,[J;CZ>/3UQ&9/HX1L.L2[!H5 M'$$FHB(;GQ1?UP'A\2NN,H%PM$N.]CD#- 82PQ7,ATCLR!?Q5D>$*_F^3QGK M=&@'P>J46!U4K)RKB[>T-EUX>._R"P+1+2&ZYT',A)':K9F(P,JKY<&5WE?* M#Q\^-*R57LG6.R=OTR34)M6F6,%D;H&.C'4.R82^FR!T_9*N?P[= M)ZD$>[A/?*4U*:R0?*:==MDLA-A[NHAF7_/ MN<%,@U9.3=G_AUUL=2TL+CG/)4S>P/(2A5=6 GE4.2K29SBR4A3]D M>M).&A3[S ^Z&%M5$BANZD4*1[ ?/8V""_S4:_=^QE"JPD!Q/[_7(8S*;*,3 MS-\:1()N<$G;^'ROR@'%;?N;D=:*!(8FCO/DX&U9+14NU+2QH%4-H+B!S[62 MH;0R69,'F.!&[3_R&;9ED.9(V N&PCX-'&O,&;H808M_PH6Y*%M*IV^36(N!X6FQ0= MOER0'_TKJ/ DY8:\-ZQ.BX/K4ELX!A>7&\%A\KL7 MX/E*:_O><&?A\E\9P[\!4$L#!!0 ( +J" E.?H!OPL0( .(, - M>&PO9KEMWDOSAR+DCO9*ZW="C<\W[ M)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3 M;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@ M:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_& M%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T08I:*Q[V M_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUS MS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D M^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>P MSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0 M_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^& M<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8 M[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( +J" E.7BKL< MP !," + 7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$ M^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8E MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:GH_ 0 / ( \ !X;"]W;W)K8F]O:RYX;6R-49:EL@9OTDUL(,BDBN0-2TN'+#4$QJ8:@+W+IGD^R[S!H)>+ MD6M#V743&4K&& 3L@!W".?W.NU:=,.$>'?)WH?NW ZT\!O1X 5OH7*M4Q_-+ M)+S$P,9M2XK.%7HR#'9 C.4?>-N)_#3[U"-L]A]&A!1ZE@MAA92XW^CYC6@\ M@2P/73>TFH=>Y!L/?P&HT=S8\?M_P!4$L#!!0 M ( +J" E,D'INBK0 /@! : >&PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&R MGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0 MDBBZ0=@S9)[NF:*'3^ 5!+ M P04 " "Z@@)399!YDAD! #/ P $P %M#;VYT96YT7U1Y<&5S72YX M;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85- MK'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+ MY8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-FI6.5Z*U .EK >MKBRAE# MVQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/) MW55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_ ML;S63AI_YHOA/UY_ 5!+ 0(4 Q0 ( +J" E,'04UB@0 +$ 0 M " 0 !D;V-0&UL4$L! A0#% @ NH(" M4UXOF@/N *P( !$ ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ NH("4YE&PO=V]R:W-H965T&UL4$L! A0#% @ NH("4Y^@&_"Q @ X@P T ( ! MB@P 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL M4$L! A0#% @ NH("4R0>FZ*M ^ $ !H ( !NQ$ M 'AL+U]R96QS+W=O9(9 0 SP, !, ( !H!( %M#;VYT96YT7U1Y<&5S72YX 8;6Q02P4& D "0 ^ @ ZA, end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.medicinova.com//20210731/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d211886d8k.htm d211886dex991.htm mnov-20210731.xsd mnov-20210731_lab.xml mnov-20210731_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d211886d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d211886d8k.htm" ] }, "labelLink": { "local": [ "mnov-20210731_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "mnov-20210731_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "mnov-20210731.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mnov", "nsuri": "http://www.medicinova.com/20210731", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d211886d8k.htm", "contextRef": "duration_2021-07-31_to_2021-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.medicinova.com//20210731/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d211886d8k.htm", "contextRef": "duration_2021-07-31_to_2021-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.medicinova.com//20210731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.medicinova.com//20210731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.medicinova.com//20210731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.medicinova.com//20210731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.medicinova.com//20210731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.medicinova.com//20210731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.medicinova.com//20210731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.medicinova.com//20210731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.medicinova.com//20210731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.medicinova.com//20210731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.medicinova.com//20210731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.medicinova.com//20210731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.medicinova.com//20210731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.medicinova.com//20210731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.medicinova.com//20210731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.medicinova.com//20210731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.medicinova.com//20210731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.medicinova.com//20210731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.medicinova.com//20210731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.medicinova.com//20210731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.medicinova.com//20210731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.medicinova.com//20210731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.medicinova.com//20210731/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001193125-21-233293-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-233293-xbrl.zip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end